Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer

Journal of Hepatology

Volumn 50, Issue 2, 2009, Pages 323-333

  Chang, Qingshan ^b   Zhang, Yadong ^a   Beezhold, Kevin J ^a,c   Bhatia, Deepak ^a   Zhao, Hongwen ^a,d   Chen, Jianguo ^e   Castranova, Vince ^a   Shi, Xianglin ^a,b   Chen, Fei ^a,b,c  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d CHINA MEDICAL UNIVERSITY   (China)

^e QIDONG LIVER CANCER INSTITUTE   (China)

Author keywords

EZH2; H3K4me3; HCC; JNK; Tumor suppressor

Indexed keywords

CYTOCHROME P450; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN METHYLATION; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DNA-BINDING PROTEINS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTONES; HUMANS; LIVER; LIVER NEOPLASMS; MALE; METHYLATION; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 8; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 58149460979     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.07.037     Document Type: Article

References (58)

1. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
2. Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6 (2006) 674-687
3. Kensler T.W., Qian G.S., Chen J.G., and Groopman J.D. Translational strategies for cancer prevention in liver. Nat Rev Cancer 3 (2003) 321-329
4. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
5. Llovet J.M., and Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (2008) S20-S37
6. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
7. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006) 1253-1267
8. Jia H.L., Ye Q.H., Qin L.X., Budhu A., Forgues M., Chen Y., et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 13 (2007) 1133-1139
9. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11 (2007) 119-132
10. Maeda S., Kamata H., Luo J.L., Leffert H., and Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
11. Sakurai T., Maeda S., Chang L., and Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 103 (2006) 10544-10551
12. Kyriakis J.M., and Avruch J. pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-l-lysine. J Biol Chem 265 (1990) 17355-17363
13. Chen F. MAPK8 (mitogen-activated protein kinase 8). Atlas Genet Cytogenet Oncol Haematol 2003; URL: http://AtlasGeneticsOncology.org/Genes/JNK1ID196.html.
14. Sabapathy K., Hochedlinger K., Nam S.Y., Bauer A., Karin M., and Wagner E.F. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 15 (2004) 713-725
15. Hess P., Pihan G., Sawyers C.L., Flavell R.A., and Davis R.J. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 32 (2002) 201-205
16. Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 (1985) 918-928
17. Yu J., Ni M., Xu J., Zhang H., Gao B., Gu J., et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2 (2002) 29
18. Zhang Y., Bhatia D., Xia H., Castranova V., Shi X., and Chen F. Nucleolin links to arsenic-induced stabilization of GADD45alpha mRNA. Nucleic Acids Res 34 (2006) 485-495
19. Chen F., Castranova V., Li Z., Karin M., and Shi X. Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic. Cancer Res 63 (2003) 7689-7693
20. Chen F., Lu Y., Zhang Z., Vallyathan V., Ding M., Castranova V., et al. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 276 (2001) 11414-11419
21. Chen F., Lu Y., Castranova V., Li Z., and Karin M. Loss of Ikkbeta promotes migration and proliferation of mouse embryo fibroblast cells. J Biol Chem 281 (2006) 37142-37149
22. Hayakawa J., Mittal S., Wang Y., Korkmaz K.S., Adamson E., English C., et al. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 16 (2004) 521-535
23. Weston C.R., and Davis R.J. The JNK signal transduction pathway. Curr Opin Cell Biol 19 (2007) 142-149
24. Kel A., Konovalova T., Waleev T., Cheremushkin E., Kel-Margoulis O., and Wingender E. Composite Module Analyst: a fitness-based tool for identification of transcription factor binding site combinations. Bioinformatics 22 (2006) 1190-1197
25. Heintzman N.D., Stuart R.K., Hon G., Fu Y., Ching C.W., Hawkins R.D., et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 39 (2007) 311-318
26. Sellers W.R., and Loda M. The EZH2 polycomb transcriptional repressor - a marker or mover of metastatic prostate cancer?. Cancer Cell 2 (2002) 349-350
27. Cao R., and Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14 (2004) 155-164
28. Tonini T., D'Andrilli G., Fucito A., Gaspa L., and Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 214 (2008) 295-300
29. Xia Y., Wu Z., Su B., Murray B., and Karin M. JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. Genes Dev 12 (1998) 3369-3381
30. Wong I.H., Lo Y.M., Zhang J., Liew C.T., Ng M.H., Wong N., et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59 (1999) 71-73
31. Su P.F., Lee T.C., Lin P.J., Lee P.H., Jeng Y.M., Chen C.H., et al. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer 121 (2007) 1257-1264
32. Zhang C., Li H., Zhou G., Zhang Q., Zhang T., Li J., et al. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells. J Pathol 212 (2007) 134-142
33. Murata H., Tsuji S., Tsujii M., Sakaguchi Y., Fu H.Y., Kawano S., et al. Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells. Lab Invest 84 (2004) 1050-1059
34. Wong C.M., Lee J.M., Ching Y.P., Jin D.Y., and Ng I.O. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 63 (2003) 7646-7651
35. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447 (2007) 425-432
36. Regha K., Sloane M.A., Huang R., Pauler F.M., Warczok K.E., Melikant B., et al. Active and repressive chromatin are interspersed without spreading in an imprinted gene cluster in the mammalian genome. Mol Cell 27 (2007) 353-366
37. Miotto B., Sagnier T., Berenger H., Bohmann D., Pradel J., and Graba Y. Chameau HAT and DRpd3 HDAC function as antagonistic cofactors of JNK/AP-1-dependent transcription during Drosophila metamorphosis. Genes Dev 20 (2006) 101-112
38. LaTulippe E., Satagopan J., Smith A., Scher H., Scardino P., Reuter V., et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62 (2002) 4499-4506
39. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
40. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100 (2003) 11606-11611
41. Lu C., Bonome T., Li Y., Kamat A.A., Han L.Y., Schmandt R., et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67 (2007) 1757-1768
42. Dukers D.F., van Galen J.C., Giroth C., Jansen P., Sewalt R.G., Otte A.P., et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 164 (2004) 873-881
43. Matsukawa Y., Semba S., Kato H., Ito A., Yanagihara K., and Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97 (2006) 484-491
44. Chen Y., Lin M.C., Yao H., Wang H., Zhang A.Q., Yu J., et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46 (2007) 200-208
45. Chen Y., Lin M.C., Wang H., Chan C.Y., Jiang L., Ngai S.M., et al. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics 7 (2007) 3097-3104
46. Sudo T., Utsunomiya T., Mimori K., Nagahara H., Ogawa K., Inoue H., et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92 (2005) 1754-1758
47. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., and Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20 (2006) 1123-1136
48. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39 (2007) 232-236
49. Schwartz Y.B., and Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 8 (2007) 9-22
50. Keshet I., Schlesinger Y., Farkash S., Rand E., Hecht M., Segal E., et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 38 (2006) 149-153
51. Chen X., Wang H., Xie W., Liang R., Wei Z., Zhi L., et al. Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China. Pharmacogenet Genomics 16 (2006) 219-227
52. Tsunedomi R., Iizuka N., Hamamoto Y., Uchimura S., Miyamoto T., Tamesa T., et al. Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol 27 (2005) 661-667
53. Xie Y., Liu J., Benbrahim-Tallaa L., Ward J.M., Logsdon D., Diwan B.A., et al. Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. Toxicology 236 (2007) 7-15
54. Anttila S., Hakkola J., Tuominen P., Elovaara E., Husgafvel-Pursiainen K., Karjalainen A., et al. Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. Cancer Res 63 (2003) 8623-8628
55. Ling G., Hauer C.R., Gronostajski R.M., Pentecost B.T., and Ding X. Transcriptional regulation of rat CYP2A3 by nuclear factor 1: identification of a novel NFI-A isoform, and evidence for tissue-selective interaction of NFI with the CYP2A3 promoter in vivo. J Biol Chem 279 (2004) 27888-27895
56. Nakajima M., Iwanari M., and Yokoi T. Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. Toxicol Lett 144 (2003) 247-256
57. Shi H., Yan P.S., Chen C.M., Rahmatpanah F., Lofton-Day C., Caldwell C.W., et al. Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res 62 (2002) 3214-3220
58. Laurent-Puig P., and Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 25 (2006) 3778-3786